- LTS and Nualtis have announced a strategic collaboration to expand large-scale manufacturing for oral thin film (OTF) therapies.
- The partnership aims to combine Nualtis’ formulation expertise with LTS’s global manufacturing capabilities.
LTS LOHMANN Therapie-Systeme AG (LTS) and Nualtis, formerly IntelGenx Corp., have entered into a strategic partnership focused on scaling oral thin film (OTF) drug delivery solutions. The collaboration is designed to provide cost-competitive, high-quality manufacturing and supply chain flexibility to pharmaceutical partners worldwide.
The agreement enables Nualtis to leverage LTS’s global manufacturing infrastructure, technology transfer experience, and scale-up capabilities. It also supports Nualtis’ goal of expanding its pipeline and accelerating commercial delivery of its OTF products.
LTS, recognised for its deep expertise in oral thin film development and manufacturing, continues to strengthen its position as a platform specialist. The company is actively investing in R&D and capacity growth to maintain leadership in patient-centric delivery technologies.
“Teaming up Nualtis’ excellent OTF formulation platform with LTS’s world-class manufacturing capabilities allows the two companies to accelerate our shared vision of bringing patient-centric therapeutical solutions to our pharma partners,” said Bas van Buijtenen, CEO of LTS.
“Nualtis is moving into a new stage of growth, and this collaboration positions us well for it,” said Dr. Michael Raven, CEO of Nualtis. “Partnering with LTS enhances our internal manufacturing capabilities and assures our partners that we can support them from early development right through to commercial-scale production.”
The companies will jointly support partners across all development stages, combining innovation with proven execution to improve treatment outcomes across multiple therapeutic areas.
Stay ahead of trends and best practices
